

[View this email in your browser](#)



Summer greetings from the RACC-trial

Dear all investigators

We are thrilled to announce that we now have reached **800 randomized** women in the RACC-trial! The RACC-trial is already the second largest trial in cervical cancer ever. Accrual rate appears to be relatively stable despite the outcomes from the SHAPE-trial and we will continue enrollment until we reach 900 patients sometime in 2025. At the end of 2024 (or early 2025), our trial statisticians will conduct a similar analysis to the one we presented in April, specifically looking into estimated RFS for the entire population.

Until then, we wish you a nice summer and we will get back with more information and updates in the fall!



Contact details

Sponsor

Henrik Falconer
henrik.falconer@sll.se

Co-PI

Sahar Salehi
sahar.salehi@sll.se

Chair translational research

Kolbrun Palsdottir
kolbrun.palsdottir@sll.se

Project manager

Katja Wiklund
katja.wiklund@sll.se

Data manager

Claudia Maes
Claudia.maes@sll.se

Central monitor

Anita Björk
anita.bjork@sll.se



This email was sent to claudia.maes@sll.se

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)

Karolinska University Hospital · Karolinska Universitetssjukhuset · Stockholm 171 76 · Sweden

